Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2019 Apr 30

PMID 31030480

Citations 7

Authors

Rupali Dewan

Abhinav Dewan

Meera Jindal

Mausumi Bhardawaj

Affiliations

Soon will be listed here.

Abstract

Background: Early diagnosis of ovarian cancer is essential for long term disease control and mortality reduction. This has been achieved using tumor markers like cancer antigen 125 (CA-125) which is elevated in malignant as well as non-malignant conditions. This dilemma led to efforts towards development of newer markers like serum human epididymis secretory protein E4 (HE4). Present study aimed to evaluate role of HE4 in diagnosing ovarian cancers and comparing it with CA-125. Methods: Serum samples from 67 patients with ovarian cancer, 42 with benign ovarian masses and 26 healthy controls were collected preoperatively and tested for serum HE4 levels and CA-125 levels. Diagnostic performance of both tumor markers (HE4/CA-125) to diagnose malignancy in ovarian masses was calculated and compared to each other. Results: Mean CA-125 and HE4 levels were significantly higher in patients with ovarian cancer than in those with benign disease (p<0.001) or healthy controls (p< 0.001). Serum HE4 levels significantly increased in epithelial ovarian cancers when compared to non-epithelial ovarian cancers (p<0.01). Using benign control as comparison, receiver operating characteristic curve (ROC) was generated to predict a cut-off value for diagnosing malignancy for serum HE4 and CA-125. Compared to CA-125, HE4 had a similar sensitivity (83.6% vs. 85.10%) and higher specificity (100% vs. 90.48%); combination of serum HE4 and CA-125 improved the sensitivity to detect ovarian cancer to 92.54%. Sensitivity of HE4 to detect early stage ovarian cancer was superior to CA-125 (92.61% vs. 63.41%). Conclusion: Serum HE4, a novel tumor marker, discriminated epithelial ovarian cancer from benign ovarian masses. HE4 levels were related to the stage and histological types with the lowest levels in mucinous epithelial ovarian cancer and non-epithelial malignancy. Measuring serum HE4 levels alongwith CA-125 may provide higher accuracy for detecting epithelial ovarian cancer particularly in the early stages.

Citing Articles

Predictive Role of HE4 in Diagnosis of Ovarian Tumors.

Kumari S, Kumari P, Pankaj S, Rani J, Abhilashi K, Choudhary V J Obstet Gynaecol India. 2024; 74(5):418-423.

PMID: 39568971 PMC: 11574215. DOI: 10.1007/s13224-023-01936-8.

Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review.

Shahbazlou S, Vandghanooni S, Dabirmanesh B, Eskandani M, Hasannia S Mikrochim Acta. 2024; 191(11):659.

PMID: 39382786 DOI: 10.1007/s00604-024-06740-3.

New use of preoperative fibrinogen in ovarian cancer management.

Wu J, Zhang Y, Liu G, Ge L Transl Cancer Res. 2023; 12(11):3105-3112.

PMID: 38130314 PMC: 10731334. DOI: 10.21037/tcr-23-908.

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses.

Jang T, Kim H, Eo W, Kim K, Lee C, Kim M J Cancer. 2023; 14(4):600-610.

PMID: 37057288 PMC: 10088533. DOI: 10.7150/jca.81174.

The Diagnostic Accuracy of Serum and Urine Human Epididymis Protein 4 (HE4) in Ovarian Cancer in 15,394 Subjects: An Updated Meta-Analysis.

Nalini N, Kumar A, Sharma S, Singh B, Singh A, Prakash J Cureus. 2022; 14(10):e30457.

PMID: 36415437 PMC: 9677808. DOI: 10.7759/cureus.30457.

References

Hamed E, Ahmed H, Sedeek O, Mohammed A, Abd-Alla A, Abdel Ghaffar H . Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013; 8:11. PMC: 3621278. DOI: 10.1186/1746-1596-8-11. View

Kirchhoff C . Molecular characterization of epididymal proteins. Rev Reprod. 1998; 3(2):86-95. DOI: 10.1530/ror.0.0030086. View

Spitzer M, Kaushal N, Benjamin F . Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med. 1998; 43(4):387-92. View

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr R . Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010; 117(3):440-5. PMC: 2873171. DOI: 10.1016/j.ygyno.2010.02.005. View

Curtin J . Management of the adnexal mass. Gynecol Oncol. 1994; 55(3 Pt 2):S42-6. DOI: 10.1006/gyno.1994.1340. View

Yu S, Yang H, Xie S, Bao Y . Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012; 50(8):1439-46. DOI: 10.1515/cclm-2011-0477. View

Wang K, Gan L, Jeffery E, Gayle M, Gown A, Skelly M . Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene. 1999; 229(1-2):101-8. DOI: 10.1016/s0378-1119(99)00035-9. View

Prat J . Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2013; 124(1):1-5. DOI: 10.1016/j.ijgo.2013.10.001. View

10.

Bast Jr R, Xu F, Yu Y, Barnhill S, Zhang Z, Mills G . CA 125: the past and the future. Int J Biol Markers. 1999; 13(4):179-87. DOI: 10.1177/172460089801300402. View

11.

Raja F, Chopra N, Ledermann J . Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012; 23 Suppl 10:x118-27. DOI: 10.1093/annonc/mds315. View

12.

Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S . The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal. 2009; 23(5):331-5. PMC: 6649112. DOI: 10.1002/jcla.20340. View

13.

Junor E, Hole D, Gillis C . Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 1994; 70(2):363-70. PMC: 2033481. DOI: 10.1038/bjc.1994.307. View

14.

Moore R, Brown A, Miller M, Skates S, Allard W, Verch T . The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108(2):402-8. DOI: 10.1016/j.ygyno.2007.10.017. View

15.

Bast Jr R, Klug T, St John E, Jenison E, Niloff J, Lazarus H . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309(15):883-7. DOI: 10.1056/NEJM198310133091503. View

16.

Hogdall E, Christensen L, Kjaer S, Blaakaer J, Kjaerbye-Thygesen A, Gayther S . CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol. 2006; 104(3):508-15. DOI: 10.1016/j.ygyno.2006.09.028. View

17.

Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M, Kitaoka Y . Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum Reprod. 2005; 20(7):1999-2003. DOI: 10.1093/humrep/deh890. View

18.

Ismail M, Rotmensch J, Mercer L, Block B, Salti G, Holt J . CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders. J Reprod Med. 1994; 39(7):510-2. View

19.

Dilek I, Ayakta H, Demir C, Meral C, Ozturk M . CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol. 2005; 27(1):51-5. DOI: 10.1111/j.1365-2257.2004.00655.x. View

20.

Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T . Histological classification of ovarian cancer. Med Electron Microsc. 2003; 36(1):9-17. DOI: 10.1007/s007950300002. View